A comparison of the efficacy and tolerability of the PCSK9 inhibitors, Alirocumab and evolocumab, in routine lipid clinic practice

2017 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    1
    Citations
    NaN
    KQI
    []